Big Data, the Louisiana Purchase, and the Wild West

Big data is the new catch phrase that everyone is talking about. But, what does it mean? Is it really new? And how can Ann Arbor life science companies take advantage of this new “gold rush?" In 2014, Venture Capital poured $400M into startups focused on big data and analytics making it the biggest area of funding in digital health.

Come to BioArbor on March 18 to hear from and talk to early veterans of the big data life science revolution.

We’ll discuss following:

• What is big data?
• Where are we in this market's “westward expansion?”
• Have the gold nuggets on the surface already been mined? What comes next?
• What are sustainable big data business models?

Speakers include veterans of Medstat and Compendia Bioscience – two Ann Arbor companies that harnessed big data to build, grow and exit big data companies.

Chris Gates was the former Director of Product Informatics at Compendia Bioscience. He currently serves as lead software engineer at the University of Michigan Bioinformatics Core in their Department of Computational Medicine & Bioinformatics.

Pat Rinvelt was the Sr. VP, Care Management Solutions at Truven Health Analytics (formerly Medstat). She currently is Executive Director, National Network of Depression Centers and co-chair, Michigan Health Information Technology Commission.

John Freshley will moderate. He helped launch Compendia Bioscience and served as its first CEO and remained as Chief Business Officer through it sale to Life Technologies. He currently serves as President & CEO of ONL Therapeutics.

Image: Camelia Boban